What the prescribing labels report
Ozempic is semaglutide approved for type 2 diabetes. The hair loss rows come from the weight-management labels for the same molecule and for tirzepatide:
- Wegovy (semaglutide). In the adult trials table, hair loss was reported by 3% of people on Wegovy and 1% on placebo. In the table for patients aged 12 and older, 4% versus 0%.[1]
- Zepbound (tirzepatide). In the adult trials table, hair loss was reported by 5%, 4% and 5% across the three doses studied, against 1% on placebo.[2]
These are the share of trial participants who reported hair loss as an adverse reaction. They do not say how much hair, how long it lasted, or whether it returned.
What a 2025 systematic review found
A systematic review in Cureus (September 2025) pulled the published evidence together[3]. It reports the tirzepatide trial figures of 4.9% to 5.3% against 0.9% on placebo, a retrospective cohort in which 14.2% of patients reported hair loss, and a signal for semaglutide in pharmacovigilance data. Where hair loss was typed, the review lists both telogen effluvium and androgenetic alopecia. On mechanism it is direct: it "is still not well established", with rapid weight loss and nutritional deficiency proposed. On recovery the review calls the evidence conflicting and limited, with case reports of regrowth alongside a cohort in which most cases had not resolved at follow-up.
Why rapid weight loss causes shedding, per dermatology sources
Shedding after a big change to the body is a described pattern with a name, telogen effluvium. The American Academy of Dermatology lists "Lost 20 pounds or more" among the stressors after which excessive shedding is common, says "Most people notice the excessive hair shedding a few months after the stressful event," and puts the recovery at six to nine months, after which the hair tends to regain its normal fullness.[4] Harvard Health gives the same shape: hair loss may not show "until two to four months after the event that caused the problem", it "rarely lasts longer than six months, although some cases last longer", and "the hair usually grows back", though "In other cases, not all hairs grow back."[5] Harvard lists extreme weight loss, an extreme change in diet and some medications among the triggers[5].
The NHS makes the general point: hair loss caused by a medical condition "usually stops or grows back once you've recovered", and it lists weight loss among the causes of temporary hair loss[6]. MedlinePlus adds the baseline: losing up to 100 hairs a day is normal, and in most people those hairs grow back[7].
So does it grow back?
For shedding that fits the telogen effluvium pattern, the dermatology sources above describe recovery over roughly six to nine months after the trigger settles[4][5]. For hair loss specifically on GLP-1 medicines, the systematic review says the evidence does not yet settle it[3]. Nobody can tell you from a web page which case yours is. The person who can is your prescriber, and what helps that conversation is a dated record rather than a memory of how it looked.
What to do

- The prescriber who started the medicine is the person to talk to before anything about it changes. Bring the dates: when you started, when shedding began, how much weight has changed.
- Start a dated photo record now. Same spot, same light, same angles, once a month. If you have an older photo from before the medicine, import it and date it so you have a real before. The photo method guide explains the setup.
- Log the shedding as something you observed, not a feeling. A daily note of light, moderate or heavy is enough to see whether it is settling by the six-month mark the sources describe.
- Ask about the whole picture. Harvard and the AAD both list other shedding triggers, including iron and thyroid problems and diet changes, and a clinician can check for those.
HairAgain is built for that record. It lines each monthly photo up with the last one, keeps an optional shed log, and shows any two months side by side with their dates. It does not estimate anything from the photo. The reading is yours and your clinician's.
Sources
Every claim above points at one of these. All accessed 2026-10-18.
- DailyMed, Wegovy (semaglutide) prescribing information, Novo Nordisk, section 6.1 Table 3 and Table 5, set ID ee06186f-2aa3-4990-a760-757579d8f77b
- DailyMed, Zepbound (tirzepatide) prescribing information, Eli Lilly, section 6.1 Table 1, set ID 487cd7e7-434c-4925-99fa-aa80b1cc776b
- Alsuwailem OA et al., "Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review", Cureus, September 2025, PMC12530271
- American Academy of Dermatology, "Do you have hair loss or hair shedding?"
- Harvard Health Publishing, "Telogen effluvium" (reviewed October 2024)
- NHS, "Hair loss"
- MedlinePlus (NIH), "Hair Loss"
HairAgain